Not so early notification in reality – we received our notification from PHARMAC at 3.02pm on the 11th April 2019.

As advised via PHARMAC proposal of 29 August 2018 and the notification of PHARMAC decision of 11 April 2019 there is to be a change in the listing and future sole supply of lamotrigine dispersible tablets 25mg, 50 mg and 100 mg.

New listing from 1 May 2019 (price & subsidy decrease only)

Logem Tab dispersible 25 mg 56                                                                  Pharmacode 2553376                Schedule price from $19.38 to $2.76

Logem Tab dispersible 50 mg 56                                                                  Pharmacode 2553384                Schedule price from $32.97 to $3.31

Logem Tab dispersible 100 mg 56                                                                Pharmacode 2553392                Schedule price from $56.91 to $4.40

Incumbent brand (all delisting 1 October 2019)

Lamictal Tab dispersible 25 mg 56                                                               Pharmacode 417866                           Schedule price $29.09

Lamotrigine-Arrow Tab dispersible 25 mg 56                                                      Pharmacode 2245515                Schedule price $20.40

Lamictal Tab dispersible 50 mg 56                                                               Pharmacode 418021                           Schedule price $47.89

Lamotrigine-Arrow Tab dispersible 50 mg 56                                                      Pharmacode 2245507                Schedule price $34.70

Lamictal Tab dispersible 100 mg 56                                                             Pharmacode 418498                           Schedule price $79.16

Lamotrigine-Arrow Tab dispersible 100 mg 56                                                    Pharmacode 2245493                          Schedule price $59.90

Reference pricing will not apply.

Instead there will be a 5 month transition period from 1 May 2019 to 30 September 2019 where incumbent brands will remain listed and funded at existing schedule pricing.

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 October 2019.

Brand switch fee will apply from 1 October 2019 to 1 January 2020.

As of the date of this notification ProPharma / PWR cannot accept Lamictal for credit under any circumstances.

From 1 May 2019 community pharmacies dispensing lamotrigine will need to support patients changing to Logem brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent brands.

In association with Teva we are pleased to advise Lamotrigine-Arrow will be supplied on a Sale or Return basis until 30 September 2019. Any full packs remaining in pharmacy on the 1st October 2019 may be returned to your wholesaler no later than Friday 11th October 2019 for credit.  (please complete a credit return form) NO LATE RETURNS WILL BE ACCEPTED.

Due to the new Logem 25mg & 50 mg pricing (both Low Cost Medicines) we are unable to set automatic replacements for those strengths. We will however set up automatic replacement for the 100mg as stocks of the incumbent 2 brands are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 October 2019. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have all three products listed and fully funded until the commencement of the sole supply we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close